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Myelodysplastic syndromes (MDS) are clonal haemato-
poietic stem cell (HSC) disorders predominating in the
elderly, characterised by ineffective haematopoiesis leading
to blood cytopaenias and progression to acute myeloid
leukaemia (AML) in one-fourth to one-third of cases.1 Their
pathophysiology is characterised by a multi-step process
involving cytogenetic changes and/or gene mutations,2 ab-
normalities of the bone marrow microenvironment3 and
widespread gene hypermethylation at advanced stages.4,5
Median age at diagnosis of MDS is w70 years and <10%
are younger than 50 years.6 The incidence of MDS is about
4 cases/100 000 inhabitants/year (reaching 40-50/100 000
in patients aged 70 years).6 There are no known ethnic
differences in the incidence of MDS, but in Asian pop-
ulations, MDS tends to occur at an earlier age, more often
with a hypocellular marrow and less often with isolated 5q
deletion (‘5q-syndrome’). Trisomy 8 also seems to occur
more frequently in Asian populations compared with
Western populations.7
The aetiology of MDS is only known in 15% of cases. An
inherited predisposition to MDS is seen in one-third of
paediatric MDS patients, including Down syndrome, Fan-
coni anaemia and neurofibromatosis. It is less frequent in
adults, but an inherited predisposition should be assessed
in MDS occurring in young adults or families with otherondence to: ESMO Guidelines Committee, ESMO Head Office, Via
CH-6900 Lugano, Switzerland
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xx - Issue xxx - 2020cases of MDS, AML or aplastic anaemia. Point mutations of
several genes including DDX 41, GATA2, RUNX 1, ANKRD 26,
ETV6 and telomerase complex genes (TERC, TERT) have
been found in such familial cases.8 Environmental factors
include previous exposure to chemotherapy (ChT), espe-
cially alkylating agents and purine analogues,9 radiotherapy
(RT) or ionising radiation10,11 and tobacco smoking.12 Rec-
ognised occupational factors include benzene and its de-
rivatives,13 and more cases of MDS are reported among
agricultural and industrial workers.12,14 Cases of ‘secondary
MDS’, particularly those occurring after ChT (therapy-
related MDS), generally have poor prognostic factors,
including complex cytogenetic findings involving chromo-
somes 5 and/or 7 and/or 17p.15
DIAGNOSIS AND PATHOLOGY/MOLECULAR BIOLOGY
Diagnosis of MDS is based on blood and bone marrow ex-
amination, showing blood cytopaenias, generally hyper-
cellular (but sometimes hypocellular) marrow with
dysplasia, with or without an excess of blasts.16
Well-established diagnostic tools for MDS with wide-
spread availability are peripheral and differential blood
counts, cytomorphology of peripheral blood and bone
marrow smears and cytogenetics of bone marrow cells [I,
A]. At diagnosis, histology of bone marrow trephine biopsies
is strongly recommended, especially to exclude other cau-
ses of cytopaenia and because of its potential prognostic
information [I, A]. In difficult cases, such as cytopaenias
with unspecific morphological changes and no cytogenetic
changes, molecular analysis by next generation sequencing
techniques to demonstrate clonality [I, A] and, in experi-
enced hands, flow cytometry of blood and marrow cells can
be useful for diagnosis [II, B].
Differential diagnoses of MDS include a history of medi-
cation or ingestion of alcohol or other drugs and exclusionhttps://doi.org/10.1016/j.annonc.2020.11.002 1
Table 1. Definition of ICUS, IDUS, CHIP and CCUS21,22
Characteristics
ICUS  Mild cytopaenia for at least 4 months (haemoglobin
<11.0 g/dl, neutropaenia <1500/ml and/or thrombo-
cytopaenia <100 000/ml)
 No or only mild (<10%) marrow dysplasia
 Marrow blasts <5%
 No clonal cytogenetic or molecular markers
 Exclusion of other diseases
IDUS  No significant cytopaenia (i.e. haemoglobin 11 g/dl,
neutrophils 1500/ml and platelets 100 000/ml)
 Marked dysplasia in >10% of neutrophilic and/or
erythroid and/or megakaryocytes lineages
 Marrow blasts <5%
 No clonal cytogenetic or molecular markers
CHIP  No significant cytopaenia
 No or only mild (<10%) dysplasia
 Marrow blasts <5%
 Presence of one or more MDS-related mutation(s)
 Clonality defined by mutation of myeloid disorder asso-
ciated genes (including particularly DNMT3A, ASXL1,
TET2, JAK2 and TP53 genes), with a VAF of between 2%
and 30%
CCUS  Cytopaenia for at least 4 months (haemoglobin<11.0 g/dl
and/or neutropaenia <1500/ml and/or thrombo-
cytopaenia <100 000/ml)
 No or only mild (<10%) marrow dysplasia
 Marrow blasts <5%
 Presence of one or more MDS-related mutation(s)
 Clonality defined by mutation of myeloid disorder asso-
ciated genes (including particularly DNMT3A, ASXL1,
TET2, JAK2 and TP53 genes), with a VAF of between 2%
and 30%
CCUS, clonal cytopaenias of uncertain significance; CHIP, clonal haematopoiesis of
indeterminate potential; ICUS, idiopathic cytopaenias of uncertain significance; IDUS,
idiopathic dysplasia of unknown significance; MDS, myelodysplastic syndromes; VAF,
variant allele frequency.
Table 2. Signs of dysplasia in myelodysplastic syndromes
Peripheral blood
 Granulocytes Pseudo Pelger-Huet cells, abnormal chromatin
clumping, hypo-/degranulation, left shift
 Platelets Giant platelets, anisometry of platelets
 Red cells Anisocytosis, poikilocytosis, dimorphic
erythrocytes, polychromasia, hypochromasia,
megalocytes, basophilic stippling, presence of
nucleated erythroid precursors, tear drop cells,
ovalocytes, fragmentocytes
Bone marrow
 Cellularity of the
marrow
Typically hypercellularity, rarely hypocellularity
 Erythropoiesis Megaloblastoid changes, multinuclearity, nuclear
budding, non-round nuclei, karyorrhexis, nuclear
bridges, atypical mitoses, sideroblastosis, ring
sideroblasts, periodic acid-Schiff-positive red cell
precursors
 Megakaryopoiesis Micromegakaryocytes, mononuclear
megakaryocytes, dumbbell-shaped nuclei,
hypersegmentation, multinuclearity with multiple
isolated nuclei
 Granulocytopoiesis Left shift, increased medullary blast count, Auer
rods or Auer bodies, hypo-/degranulation,
pseudo-Pelger cells, nuclear anomalies
(e.g. hypersegmentation, abnormal chromatin
clumping), deficiency ofmyeloperoxidase, increase
and morphological abnormality of monocytes
Annals of Oncology P. Fenaux et al.of other diseases, including autoimmune disorders, renal
failure, malignancies, chronic infections, aplastic anaemia
and paroxysmal nocturnal haemoglobinuria (PNH).17
MDS should be classified according to the World Health
Organization (WHO) criteria16 with prognosis established by
the international prognostic scoring system (IPSS)18 or
rather, its revised version (IPSS-R).19 Prognosis is based on
the marrow blast percentage, number and extent of cyto-
paenias, and cytogenetic abnormalities, which are grouped
in the IPSS-R.18,19 Treatment varies from symptomatic
therapy for cytopaenias, especially transfusions, to alloge-
neic stem cell transplantation (allo-SCT).
Peripheral blood counts and differential blood counts
Almost all patients with MDS have blood cytopaenias,
mostly anaemia (usually macrocytic) with or without other
cytopaenias.
Laboratory parameters
Laboratory values supporting or excluding the diagnosis of
MDS are ferritin, transferrin and transferrin saturation,
reticulocyte counts, vitamin B12 and folate concentrations,
haptoglobin, and creatinine levels. They can exclude the
differential diagnoses of iron deficiency anaemia, haemo-
lytic anaemia, vitamin B12 or folate deficiency and renal
anaemia. If MDS is diagnosed, ferritin and lactate dehy-
drogenase (LDH) also have some prognostic value, and the
erythropoietin (EPO) level can support a decision for or
against treatment with erythropoiesis-stimulating agents
(ESAs). Diagnostic work-up for PNH may be considered in
cases with a clinical suspicion as small PNH clones can
accompany MDS.
Cytomorphology
The hallmarks of cytomorphology in MDS are dysplastic
features in 10% of marrow and/or peripheral blood cells
of erythroid, granulocytic or megakaryocytic lineage.
Marrow histology of trephine biopsies is of additional value.
In early MDS with only mild morphological abnormalities,
certain cases with persistent, unexplained cytopaenias are
called idiopathic cytopaenias of uncertain significance
(ICUS). In patients with marrow dysplastic features but no
or very mild peripheral blood cytopaenias and normal kar-
yotype, idiopathic dysplasia of unknown significance
(IDUS)20 can be diagnosed if no other cause of dysplasia is
apparent (see Table 1). Patients with clonal somatic muta-
tions and cytopaenias without dysplastic features and
normal karyotype [clonal cytopaenias of uncertain signifi-
cance (CCUS)] constitute a third group of patients with a
higher risk of progression to MDS.21,22
When evaluating MDS blood films and marrow slides,
certain cytological abnormalities should be considered (see
Table 2). For an MDS diagnosis, the recommended number
of cells to be reviewed per slide is 200 for the blood film
and up to 500 for bone marrow.23 The marrow blast count is
crucial given its important prognostic value. ‘Blasts’ should
include agranular blasts, myeloblasts and promonocytes but2 https://doi.org/10.1016/j.annonc.2020.11.002not promyelocytes. Staining for iron with Prussian blue
(Perls stain) should always be carried out in lower-risk MDS
in order to evaluate the presence of ring sideroblasts.Volume xxx - Issue xxx - 2020
P. Fenaux et al. Annals of OncologyHistopathology
In the European Union (EU), contrary to the United States,
MDS are mainly followed-up by bone marrow aspirate
rather than biopsy. Bone marrow trephine biopsy, however,
is useful at diagnosis to assess cellularity and fibrosis. In
case of hypocellular aspirates or dry puncture, it allows a
diagnosis of hypoplastic MDS or fibrotic MDS. It may also
exclude other differential diagnoses and may provide
additional information on dysplastic features (mainly of
megakaryocytes) and prognostic information, especially by
showing fibrosis. It is therefore strongly recommended in
addition to bone marrow aspiration at diagnosis.24,25Cytogenetics
In MDS, clonal chromosome abnormalities are observed in
30% to >80% of patients.26 In the remaining 20%-70% of
patients with a normal karyotype, sub-microscopic alter-
ations such as point mutations, microdeletions orAnalysis of at least 10 (-20) m
or 20 (-25) if a normal ka
Normal karyotype 
or insuffi cient number of metaphases
FISH
Optional for all subtypes
Probes for 5q31, cen7, 7q31, cen8, 
TP53, 20q, cenY
Cytogenetics: at least two differe
(if cultures were established, additional 24
Figure 1. Recommended standard algorithm for cytogenetic analysis in MDS.29
FISH, fluorescence in situ hybridisation; ISCN, International System for Human Cytoge
Volume xxx - Issue xxx - 2020amplifications, epigenetic changes or copy number neutral
loss such as uniparental disomy (UPD) provide the genetic
basis for the disease.2,27 Currently, standard karyotype still
has the highest prognostic value of all IPSS-R parameters.19
Chromosome banding analysis is carried out on dividing
metaphase cells. Whenever possible, 20-25 metaphases
should be analysed so as not to miss smaller cell clones that
are frequent, especially in low-risk MDS. Complex abnor-
malities are defined as three or more independent abnor-
malities in at least two metaphases.28 Cytogenetic analysis
should follow minimal standards fixed by the ‘Workpackage
Cytogenetics’ of the European LeukemiaNet (see Figure 1).29
In an international database of 2124 patients with MDS,
52% had one or more clonal cytogenetic abnormalities.
Abnormal karyotypes were clearly associated with the
severity of MDS, increasing with marrow blast count and
the intensity of dysplasias.26
Several independent studies have proven the dismal
outcome related to complex abnormalities.26,30,31 Complexetaphases (if abnormal) 
ryotype is diagnosed
Abnormal karyotype
Documentation and reporting 
according to ISCN
nt cell cultures (24h and 48h)
h and 72h cultures are recommended)
netic Nomenclature; MDS, myelodysplastic syndromes.
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Table 3. Most frequent somatic mutations observed in MDSa,35,36





















Signalling molecules NRAS/KRAS 10
Cohesin complex STAG2 5-7
MDS, myelodysplastic syndromes.
a Other mutations are seen in <5% of cases.
Annals of Oncology P. Fenaux et al.abnormalities can be further subdivided by the presence or
absence of TP53 mutations, the number of cytogenetic
changes and severe anaemia.32
Assessing karyotype during follow-up is also useful as
cytogenetic progression is associated with poorer prognosis,
while cytogenetic response after a given treatment may be
associated with a better outcome.31,33,34
Molecular genetics
Acquired molecular mutations are seen in 80%-90% of MDS
patients,35,36 affecting epigenetic regulation and chromatin-
remodelling (TET2, DNMT3A, ASXL1, IDH1/2, EZH2),
pre-mRNA splicing factors (SF3B1, SRSF2, U2AF1), tran-
scription (TP53, RUNX1) and signal transduction (NRAS,
CBL), and can demonstrate clonal disease (Table 3). The
most frequent mutations (each present in >10% of
patients) affect TET2, SF3B1, ASXL1, SRSF2, DNMT3A and
RUNX1, but approximately one or more of around 30 genes
are mutated in >1% of patients. Forty percent of patients
have more than one mutation. Most mutations, except
SF3B1, carry a poor prognosis, and prognosis is worse with a
larger number of mutations.35 Molecular profiling can also
be a valuable diagnostic tool if MDS is uncertain in ICUS or
IDUS,37 but mutations have limited impact on the clinical
management in most cases. Exceptions are SF3B1 mutation
in lower-risk MDS (associated with a favourable prognosis
and likely to respond to luspatercept) and TP53 mutation in
lower-risk MDS with del(5q), associated with an increased
risk of leukaemic transformation, lower cytogenetic
response rate and shorter response duration to lenalido-
mide (LEN).38
Clonal haematopoiesis of indeterminate potential
Somatic mutations seen in myeloid neoplasias have been
observed in elderly healthy persons (10%-13% of those
aged 70-80 years).39-41 The most frequently affected gene is
DNMT3A, followed by TET2, ASXL1, and less often, JAK2,
PPM1D, SF3B1, SRSF2 and TP53. Most patients have only
one mutation, and generally with variant allele frequency
(VAF) of 10%. Since individuals examined had no obvious
haematological disease, the term ‘clonal haematopoiesis of
indeterminate potential’ (CHIP) was established.42 CHIP is4 https://doi.org/10.1016/j.annonc.2020.11.002associated with a 13-fold increased risk of developing a
haematological neoplasia and a 1.4-fold risk of death also
related to an increased incidence of atherosclerotic car-
diovascular disease.43
Patients with CHIP and unexplained cytopaenia but no
morphological evidence for myelodysplasia have been
classified as CCUS. Over 30% of patients with unexplained
cytopaenias appear to have CCUS, with an increased risk of
developing myeloid neoplasia depending on the type of
mutation.37,44Flow cytometry
Flow cytometry abnormalities of myeloid precursors may
support a diagnosis of MDS, but this method should be
used by experts according to published guidelines, and
should not be used for the evaluation of the percentage of
bone marrow blasts.45,46Classification
The current WHO classification of MDS16 divides MDS with
<5% blasts into those with single lineage or multilineage
dysplasia (Table 4). In MDS with single lineage dysplasia,
patients with ring sideroblasts (MDS-RS) have a low AML
progression rate and generally have a prolonged overall
survival (OS) if SF3B1 mutation is present and is isolated or
at least not associated with poor prognosis mutations such
as RUNX1 mutation. The entity of del(5q) MDS is not
defined by morphological criteria but by the presence of
del(5q), making cytogenetic analysis mandatory. This clas-
sification has recognised entities with germline predisposi-
tion (Table 5).8 Finally, chronic myelomonocytic leukaemia
has been moved to myelodysplastic/myeloproliferative
neoplasms.16Recommendations Diagnosis is based on blood count, marrow aspirate and
marrow karyotype [I, A].
 Bone marrow biopsy is recommended at diagnosis [I, A].
 Molecular biology is useful for diagnosis if blood and
marrow tests are inconclusive [I, A].
 Flow cytometry of blood and marrow cells is useful for
diagnosis in experienced hands [II, B].STAGING AND RISK ASSESSMENT
The natural course of MDS is highly variable, with survival
ranging from a few weeks to many years. Causes of death
are mainly related to MDS in higher-risk patients, while a
large proportion of patients with lower-risk MDS die of non-
MDS causes, i.e. comorbidities associated with the typical
age of MDS patients.47,48 Median OS is 15-30 months and
the 5-year AML progression rate is 25%-35%. Bone marrow
failure (infection and haemorrhage) is the leading cause of
death before AML progression.49
The main risk factors, allowing an individual risk-adapted
treatment strategy, are cytogenetic abnormalities, marrowVolume xxx - Issue xxx - 2020
Table 4. The WHO 2016 classification of MDS16
Name Dysplastic lineages Cytopaeniasa Ring sideroblasts
as % of marrow
erythroid
elements
BM and PB blasts Cytogenetics by
conventional
karyotype analysis
MDS-SLD 1 1 or 2 <15%/<5%b BM <5%, PB <1%, no Auer rods Any, unless fulfils criteria for
MDS with isolated del(5q)
MDS-MLD 2 or 3 1-3 <15%/<5%b BM <5%, PB <1%, no Auer rods Any, unless fulfils criteria for
MDS with isolated del(5q)
MDS-RS-SLD 1 1 or 2 15%/5%b BM <5%, PB <1%, no Auer rods Any, unless fulfils criteria for
MDS with isolated del(5q)
MDS-RS-MLD 2 or 3 1-3 15%/5%b BM <5%, PB <1%, no Auer rods Any, unless fulfils criteria for
MDS with isolated del(5q)
MDS with isolated del(5q) 1-3 1-2 None or any BM <5%, PB <1%, no Auer rods Del(5q) alone or with one
additional abnormality
except -7 or del(7q)
MDS-EB-1 0-3 1-3 None or any BM 5%-9% or PB 2%-4%, no Auer rods Any
MDS-EB-2 0-3 1-3 None or any BM 10%-19% or PB 5%-19% or Auer rods Any
MDS-U with 1% blasts 1-3 1-3 None or any BM <5%, PB ¼ 1%c, no Auer rods Any
MDS-U with single lineage
dysplasia and pancytopaenia
1 3 None or any BM <5%, PB <1%, no Auer rods Any
MDS-U based on defining
cytogenic abnormality
0 1-3 <15%d BM <5%, PB <1%, no Auer rods MDS-defining abnormality
Refractory cytopaenia of
childhood
1-3 1-3 None BM <5%, PB <2% Any
BM, bone marrow; MDS, myelodysplastic syndromes; MDS-EB, myelodysplastic syndrome with excess blasts; MDS-MLD, myelodysplastic syndrome with multilineage dysplasia;
MDS-RS-MLD, myelodysplastic syndrome with ring sideroblasts with multilineage dysplasia; MDS-RS-SLD, myelodysplastic syndrome with ring sideroblasts with single lineage
dysplasia; MDS-SLD, myelodysplastic syndrome with single lineage dysplasia; MDS-U, myelodysplastic syndrome unclassifiable; PB, peripheral blood; WHO, World Health
Organization.
a Cytopaenias defined as haemoglobin <10 g/dl, platelet count <100  109/l and absolute neutrophil count <1.8  109/l; rarely, MDS may present with mild anaemia or
thrombocytopaenia above these levels. PB monocytes must be <1  109/l.
b If SF3B1 mutation is present.
c 1% PB blasts must be recorded on at least two separate occasions.
d Cases with 15% ring sideroblasts have significant erythroid dysplasia and are classified as MDS-RS-SLD.
Reprinted with permission.16
P. Fenaux et al. Annals of Oncologyblasts percentage and number and severity of cytopaenias.
The IPSS18 and IPSS-R19 (Table 6) are based on these vari-
ables. They have been validated in external series50 and
their use is strongly recommended for planning treatment51




disorder or organ dysfunction
 AML with germline CEBPA mutation





 Myeloid neoplasms with germline RUNX1
mutationa
 Myeloid neoplasmswith germlineANKRD26
mutationa





 Myeloid neoplasms with germline GATA2
mutation
 Myeloid neoplasms associated with BM
failure syndromes
 Myeloid neoplasms associated with telo-
mere biology disorders
 Juvenile myelomonocytic leukaemia asso-
ciated with neurofibromatosis, Noonan
syndrome or Noonan syndrome-like
disorders
 Myeloid neoplasms associated with Down
syndromea
AML, acute myeloid leukaemia; BM, bone marrow.
a Lymphoid neoplasms also reported.
Reprinted with permission.16
Volume xxx - Issue xxx - 2020groups (very low-, low-, intermediate-, high- and very high-
risk), with clear differences in OS and risk of progression to
AML,19 and offers better prognostic classification than the
IPSS. For therapeutic purposes, the term ‘lower-risk’ MDS
generally applies to cases with IPSS-R up to 3.5 including
very low- and low-risk and part of intermediate-risk IPSS-R
patients. ‘Higher-risk’ MDS includes patients with IPSS-R
4.0, i.e. high- and very high-risk, and the remaining
intermediate-risk IPSS-R patients. There is obviously some
uncertainty for intermediate-risk IPSS-R patients where the
treatment approach should take additional factors into
account.
Other factors for prognosis and treatment choice,
particularly for intermediate-risk patients, include patient-
related characteristics such as age,19 Eastern Cooperative
Oncology Group performance status (PS)19 and comorbid-
ities.52 Other disease-related factors include multilineage
dysplasia, red blood cell transfusion dependence (RBC-TD),
serum LDH, bone marrow fibrosis,52 flow cytometry
immunophenotyping53 and increasingly, gene somatic mu-
tation profiling and copy number.2,35,54 Data on the inde-
pendent prognostic impact of somatic mutations are still
lacking and so their use in routine practice to guide thera-
peutic decisions is not recommended [II, B] except for
SF3B1 in lower-risk MDS, TP53 mutation in lower-risk MDS
with del(5q) or MDS with complex karyotype [I, A] and IDH1
and IDH2 mutations as these can be targeted by specifichttps://doi.org/10.1016/j.annonc.2020.11.002 5
Table 6. IPSS-R for MDS19
Prognostic characteristic Points
0 0.5 1 1.5 2 3 4
Cytogenetic risk categorya Very good Good Intermediate Poor Very poor
Blasts in bone marrow (%) 2 >2-5 5-10 >10
Haemoglobin (g/dl) 10 8-<10 <8
Platelet count (109/l) 100 50-<100 <50
Absolute neutrophil count (109/l) 0.8 <0.8
IPSS-R risk group Score Median OS (years) Median time to 25%
AML evolution (years)
Very low 1.5 8.8 NR
Low >1.5-3 5.3 9.4
Intermediate >3-4.5 3.0 2.5
High >4.5-6 1.6 1.7
Very high >6 0.8 0.7
AML, acute myeloid leukaemia; IPSS-R, revised international prognostic scoring system; MDS, myelodysplastic syndromes; NR, not reached; OS, overall survival.
a Very good: -Y and del(11q) as single abnormalities; good: normal, del(5q), del(12p) and del(20q) as single abnormalities, double abnormalities including del(5q); intermediate:
del(7q), þ8, þ19, i(17q) and any other single abnormalities, any other double abnormalities; poor: -7 and inv(3)/t(3q)/del(3q) as single abnormalities, double abnormalities
including -7/del(7q), complex (3 abnormalities); very poor: >3 abnormalities.
Reprinted with permission.19
Annals of Oncology P. Fenaux et al.inhibitors. The diagnostic strategy may be adapted accord-
ing to the availability of new targeted therapies.
Finally, most prognostic factors in MDS have been
established independently of treatment, particularly in co-
horts receiving mostly supportive care. With the availability
of treatments having an impact on disease evolution,
including allo-SCT and hypomethylating agents (HMAs),
factors that may be prognostic in patients treated with
these interventions are starting to be defined.
Recommendations IPSS-R is required for prognostic evaluation [I, A].
 Molecular analysis may add prognostic value [II, B], espe-
cially for TP53 [in del(5q) MDS] and SF3B1 mutations in
patients with <5% blasts [I, A].
TREATMENT
Response criteria in MDS
Response criteria to treatment in MDS are based on recom-
mendations of an international working group (IWG 2006).55
These criteria define (i) responses aimed at modifying the
disease course [mainly allo-SCT, intensive ChT and HMAs,
including complete remission (CR), partial remission (PR),
stable disease (SD) and progression], and (ii) improvement of
cytopaenias (‘haematological improvement’ or HI) in one or
several lineages (erythroid, platelet and neutrophil re-
sponses).These recommendations are particularly adapted to
treatments which, like growth factors, can improve these
cytopaenias with no obvious effect on the disease course.
While CR and PR are generally associated with improvement
in cytopaenias, the latter type of response is often defined as
‘stable disease with HI (on the erythroid and/or platelet and/
or neutrophil) lineage’. An international group ofMDS experts
has recently proposed a revision to these criteria (IWG
2018).566 https://doi.org/10.1016/j.annonc.2020.11.002Treatment of higher-risk MDS patients
Higher-riskMDS carries amajor riskof progression toAMLand
short survival, and treatment should aim to modify the dis-
ease course, with options including allo-SCT, HMAs and, less
frequently, ChT (mainly intensive anthracycline-cytarabine
combinations).57 In most patients with higher-risk MDS,
HMAs are the first-line reference treatment (Figure 2).
HMAs. In patients with higher-risk MDS without major
comorbidities who are not immediately eligible for allo-SCT,
azacitidine is recommended [I, A]. The use of azacitidine
may be preferable compared with the alternative HMA,
decitabine, since findings from a randomised trial showed
that azacitidine was superior to conventional care regimens
[i.e. supportive care, low-dose cytarabine (LDAC) and AML-
like ChT],58,59 whereas there was no clear survival advan-
tage with decitabine over conventional treatment in two
phase III trials. Of note, while the pivotal AZA-001 phase III
trial58 suggested that azacitidine could yield a median OS of
24 months in higher-risk MDS, most large ‘real life’ studies
have suggested a median OS of 15-18 months, a difference
often observed between patients included in clinical trials
versus all-comers.60
As most patients only respond to azacitidine after several
courses, at least six courses are recommended as part of the
following schedule: azacitidine 75 mg/m2/day subcutane-
ously for 7 consecutive days every 28 days [II, B]. However,
‘5-2-2’ regimens (from Monday to Friday, and Monday and
Tuesday of the following week) are often easier to apply
and are considered acceptable.
Besides induction of CR and PR, achievement of HI ac-
cording to IWG 2006 criteria is associated with a prolon-
gation of survival compared with supportive care or LDAC
[III, B].61
The use of 2-6 cycles of azacitidine is quite common
before haematopoietic stem cell transplantation (HSCT) to
reduce blasts in bone marrow or for logistical reasons (toVolume xxx - Issue xxx - 2020
Very frail patients
Other patients
Patients of ≤70 years 
and no unfavourable karyotype
Patients of >70 years or younger 
but without a donor for allo-SCT
Fit patients of ≤70 years 
(or sometimes slightly older if very fi t) 
with a donor for allo-SCT
allo-SCT [I, A]
preceded or not by ChT 
or HMA to reduce blast 
percentage [III, A]
Supportive care:
RBC transfusions [IV, A], 
antibiotics, etc
AML-like ChT [I, B] or 
azacitidine [I, A]
Azacitidine [I, A]
(at least six cycles)  
Doses can be reduced in 
relatively frail patients
In case of failure or relapse, 
consider clinical trial or 
symptomatic treatment
Higher-risk MDS
(IPSS-R very high-, high- and some intermediate-riska)
Figure 2. Treatment algorithm for higher-risk MDS.
allo-SCT, allogenic stem cell transplant; AML, acute myeloid leukaemia; ChT, chemotherapy; HMA, hypomethylating agent; IPSS-R, revised international prognostic
scoring system; MDS, myelodysplastic syndromes; RBC, red blood cell.
a For IPSS-R intermediate-risk MDS patients, whether they should initially receive treatment for lower-risk MDS or higher-risk MDS is also based on other factors
including age, comorbidities, importance of cytopaenias, somatic mutations, effect of first-line treatment, etc.
P. Fenaux et al. Annals of Oncologyallow time to find an adequate SCT donor). Its potential
risks and benefits over no treatment are currently being
evaluated in clinical trials [III, B].
AML-like ChT. AML-like intensive ChT has a limited indication
in patients with higher-risk MDS. In particular, MDS patients
with an unfavourable karyotype show few CRs and shorter CR
duration than those with a normal karyotype.62-64 It can be
envisaged forfit patients (generally<70 years of age)without
unfavourable cytogenetics (especially patients with a normal
karyotype) and>10%marrowblasts, preferably as a bridge to
allo-SCT [I, B].
Suggested regimens with equivalent efficacy are combi-
nations of cytarabine with idarubicin, or fludarabine [IV, B].57
A direct comparison between AML-like ChT and azaciti-
dine has been carried out in a small number of MDS pa-
tients in one randomised phase III trial. This suggested a
superiority of the HMA in terms of survival (but not CR rate)
without reaching statistical significance, but the number of
patients was too small to draw any definitive conclusions.58
A retrospective comparison of AML-like ChT versus decita-
bine was carried out in two groups of matched MDS pa-
tients, and while CR rates were equivalent, a survival
advantage was seen only with the use of an HMA.65
Recently, CPX 351, an encapsulated form of daunorubicin
and cytarabine, proved superior to conventionalVolume xxx - Issue xxx - 2020daunorubicin and cytarabine in AML with MDS features and
AML post-MDS (AML with myelodysplasia-related changes
according to WHO 2016 classification16), and it is approved
by the Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) in those AML subsets,
including therapy-related AML.66 Whether it is also superior
to conventional ChT in higher-risk MDS needs to be
demonstrated.Low-dose ChT. LDAC (generally cytarabine 20 mg/m2/day
for 10-14 days/4 weeks) was inferior to azacitidine (in terms
of response and survival) in a randomised phase III study,58
especially in patients with unfavourable cytogenetics.67,68New treatments (especially in combination with an HMA).
Clinical trials are testingwhether the addition of another drug
to azacitidine can improve outcomes, but so far no combi-
nation has demonstrated a clear advantage over azacitidine
alone, although some are promising in elderly patients with
AML treated with an HMA-based approach.69-71 New HMAs
with a longer half-life (potentially increasing the hypo-
methylating effect) are currently being tested in MDS (and
AML), especially oral drugs.72,73
IPSS higher-risk MDS patients who fail to respond to
HMAs have a very poor survival (median <6 months) unlesshttps://doi.org/10.1016/j.annonc.2020.11.002 7
Annals of Oncology P. Fenaux et al.they are potentially eligible for allo-SCT.74 The recom-
mended approach is to enrol these patients into a clinical
trial with investigational agents [IV, B].74
The IDH1 inhibitor, ivosidenib, and IDH2 inhibitor, enasi-
denib, have shown significant activity in AML with the
respective mutations and are approved by the FDA in those
settings.75,76 They are also being tested in clinical trials in
MDS, which carries IDH1/2 mutations in around 15% of
cases. Of note, those mutations may be absent at HMA
onset and appear later in the disease course at HMA failure.
The bcl2 inhibitor, venetoclax, is approved by the FDA in
combination with an HMA in elderly patients with AML and
is also being tested in higher-risk MDS, especially in com-
bination with azacitidine.71
allo-SCT. allo-SCT remains the only potentially curative
treatment of higher-risk MDS patients [I, A], but its major
obstacle is age as most MDS patients are >70 years. Co-
morbidity, age, IPSS-R score, cytogenetics, mutations
including TP53 mutation,77 conditioning regimen and donor
selection are predictors of post-transplant outcome78,79 and
should be considered during the decision process. All pa-
tients with higher-risk MDS up to 70 years (although
particularly ‘fit’ patients aged >70 years can sometimes be
considered) should be evaluated for allo-SCT eligibility at
diagnosis and whenever required during the disease course.
Human leukocyte antigen (HLA)-identical (or single antigen
mismatched) siblings or matched unrelated individuals
should be considered as suitable donors [I, A].79 Hap-
loidentical donors and, less often, cord blood are now
widely used as alternative donors with comparable out-
comes [II, B].
Regarding conditioning regimens, whether reduced-
intensity conditioning (RIC) or myeloablative approaches
should be used is often disputed. The relapse risk seems to
be higher in patients receiving RIC; therefore, patients aged
<55 years and without comorbidities should probably be
offered myeloablative HSCT [II, B].
It is debated whether treatment aimed at reducing the
blast count should be carried out before allo-SCT with AML-
like ChT or HMAs. This is generally considered when
marrow blasts are >10%, especially for non-myeloablative
allo-SCT [III, A].80
It is now widely accepted that systemic iron overload
contributes to negative outcomes after allo-HSCT in MDS.81
Elevated labile plasma iron levels before or during allo-HSCT
predict an increased incidence of infection-related non-
relapse mortality and a decreased OS in patients with AML
or MDS. Therefore, eligible patients should receive appro-
priate iron chelation, at least until the onset of conditioning
treatment [III, B].81,82
Treatment of lower-risk MDS
In lower-risk MDS, the risk of AML progression is lower, and
around half of elderly patients die of causes other than MDS
or AML. The main priority is therefore generally the treat-
ment of cytopaenias, mainly of anaemia (usually the pre-
dominant cytopaenia), and improvement in quality of life8 https://doi.org/10.1016/j.annonc.2020.11.002(QoL). Still, some of these patients may be identified as
having a poorer prognosis, either by their IPSS-R score19 or
by other biological characteristics like somatic mutations83
or subsequently by their resistance to first-line treat-
ment,84 and may benefit from treatments generally applied
to higher-risk MDS [IV, C]. This applies particularly to pa-
tients with an intermediate IPSS-R (Figure 3).
Anaemia due to failure of specific treatments often re-
quires repeated RBC transfusions, leading to potential iron
overload.58
Treatment of anaemia.
RBC transfusions or drugs? Chronic RBC transfusions can
be considered as the sole treatment of anaemia in lower-
risk MDS as very few drugs are approved in this setting
and none have demonstrated a survival improvement
except ESA. However, repeated RBC transfusions are asso-
ciated with chronic anaemia, leading to excessive morbidity,
and they cannot completely correct impaired QoL.85,86 Iron
overload due to RBC transfusions may also be deleterious to
various organs.85,87 Receiving ESAs has no impact on pro-
gression to AML but is an independent, favourable prog-
nostic factor for survival [IV, B].88-91
First-line treatment of anaemia in lower-risk MDS.
Patients without del(5q): ESAs. ESAs, i.e. recombinant EPO
or darbepoetin (DAR), remain the first choice treatment of
anaemia in most lower-risk MDS without del(5q).88 Weekly
doses of 30 000-80 000 units of EPO or 150-300 mg of DAR
injection yield 40%-60% erythroid responses according to
IWG 2006 response criteria55 when the baseline EPO level is
low (<200-500 U/l) and transfusion requirement is absent
or limited since low baseline serum EPO level and low or no
RBC transfusion requirement are the two main prognostic
factors of response to ESAs [I, A].86,88-90,92,93
Efficacy of ESAs can be improved by the addition of
granulocyte colony-stimulating factor (G-CSF),90,94 but there
are no data showing that one ESA is superior to another.
Only one ESA, i.e. EPO alpha (and its biosimilars), is formally
approved by the EMA for lower-risk MDS patients with
serum EPO levels below 200 U/l.92
Responses to ESA occur within 8-12 weeks of treatment.
Median duration of response is 20-24 months.86,88-90,92
Lower-risk MDS with del(5q): LEN. Anaemia of lower-risk
MDS with del(5q) is associated with lower response rates
and significantly shorter responses to ESA compared with
other lower-risk MDS.95 However, it responds to LEN in
60%-65% of patients, with a median duration of RBC
transfusion independence (RBC-TI) of 2-2.5 years [I, A].96,97
The recommended initial dose is 10 mg/day for 3 weeks
every 4 weeks.98 Cytogenetic response (CyR) is achieved in
50%-75% of patients (including 30%-45% complete CyR).
TP53 gene mutations, found in w20% of lower-risk MDS
with del(5q), confer resistance to LEN and a higher risk of
AML progression.38 Thus, patients with del(5q) lower-risk
MDS harbouring or developing a TP53 mutation (during
LEN treatment) require intensified disease surveillance,Volume xxx - Issue xxx - 2020
Lower-risk MDS
(IPSS-R very low-, low- and some intermediate-riska)
Symptomatic thrombocytopaenia Symptomatic neutropaenia
Symptomatic anaemia 
(generally if Hb <10 g/dl)
Moderate and asymptomatic 
cytopaenias
Androgens [III, C]
TPO-RAs if marrow blasts <5% [II, C]
ATG if favourable features [II, C]
Azacitidine if approved [III, C]
Broad spectrum antibiotics if fever [I, A] 
Short-term G-CSF [III, C]
ATG if favourable features [III, C]













EPO ± G-CSF (low success rate) 
or second-line treatment
EPO ± G-CSFIf failure or relapse
EPO ± G-CSFSecond-line treatment EPO ± G-CSFDel(5q)EPO ± G-CSFNo del(5q)
ATG ± cyclosporine [II, B]
(age <65–70 years and 





Azacitidine (if approved) [II, B] 
or clinical trial with azacitadine, 
lenalidomide ± EPO [II, B], 
luspatercept (if MDS-RS) [I, A] 
or experimental drug
Figure 3. Treatment algorithm for lower-risk MDS.
ATG, antithymocyte globulin; EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor; Hb, haemoglobin; IPSS-R, revised international prognostic scoring
system; MDS, myelodysplastic syndromes; MDS-RS, myelodysplastic syndrome with ring sideroblasts; RBC, red blood cell; TPO-RA, thrombopoietin receptor agonist.
a For IPSS-R intermediate-risk MDS patients, whether they should initially receive treatment for lower-risk MDS or higher-risk MDS is also based on other factors
including age, comorbidities, importance of cytopaenias, somatic mutations, effect of first-line treatment, etc.
P. Fenaux et al. Annals of Oncologyincluding regular bone marrow assessment of clonal evo-
lution [III, A]. Patients with a chromosomal abnormality in
addition to del(5q) appear to have similar outcomes to
those with isolated del(5q), except for some additional
abnormalities like þ8,97 7 or del(7q), or when there are
two or more additional abnormalities, but those patients
are not classified as lower-risk MDS.96,97
Grade 3 or 4 neutropaenia and thrombocytopaenia, seen
in w60% of patients during the first weeks of treatment,
constitute the most common adverse events of LEN.96,97
Close monitoring of blood counts is therefore required
during this period, with dose reduction and/or addition of
G-CSF if required.
In the EU, LEN is approved for the treatment of lower-risk
MDS with del(5q) and RBC-TD only after failure or ineligi-
bility to ESA.
Second-line treatments for anaemia in lower-risk MDS.
Patients without del(5q).Treatment after ESA failure (primary
or secondary resistance) in patients who remain with IPSS low
or intermediate-1 MDS is disappointing, with most patients
eventually requiring long-term RBC transfusions. Second-lineVolume xxx - Issue xxx - 2020treatments currently used, but not approved in most coun-
tries, include anti-thymocyte globulin (ATG), HMAs and LEN.
ATG,  cyclosporine, can yield an erythroid response
(associated with response of other cytopaenias, especially
thrombocytopaenia) in 25%-40% of patients [II, B].99-101 ATG
results are better in relatively young (<65 years), lower-risk
MDS patients with a recent RBC transfusion history, normal
karyotype (or possibly trisomy 8), no excess blasts and HLA
DR15 genotype, and in patients with thrombocytopaenia, a
small PNH clone or with marrow hypocellularity [III, B].102
Therefore, this treatment is generally proposed to a minor-
ity of patients. As in aplastic anaemia, horse ATG appears to
achieve better results than rabbit ATG.101
HMAs yield RBC-TI in 20%-40% of patients,103,104 and
may also improve other cytopaenias in lower-risk MDS [III,
B].105 They are approved in this setting in several countries,
including the United States, but not in Europe.
LEN yields an RBC-TI in 25%-30% of lower-risk MDS pa-
tients without del(5q) resistant to ESA,106,107 and the
combination of LEN and ESA may yield higher RBC-TI rates
than LEN alone in this setting [I, B].108 However, LEN is not
approved in non-del(5q) patients.https://doi.org/10.1016/j.annonc.2020.11.002 9
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results in RBC transfusion-dependent, lower-risk MDS, with
erythroid response and RBC-TI of 63% and 38%, respectively,
with limited toxicity in a phase II study, and even better
results in patients with MDS-RS or SF3B1 mutation. Results
were confirmed in a phase III placebo-controlled randomised
study of luspatercept in RBC transfusion-dependent IPSS-R
very low-, low- or intermediate-risk MDS-RS or with SF3B1
mutation refractory to ESA,109 and this drug has recently
been approved in this setting by the FDA and EMA [I, A].110
Patients with del(5q). Resistance to LEN in lower-risk MDS
with del(5q) is associated with a poor prognosis, even if no
immediate progression to high-risk MDS is observed. Pa-
tients with TP53 gene mutation may have a particularly
poor outcome38 and are considered candidates for ap-
proaches that have demonstrated a survival benefit in
higher-risk MDS, including HMAs, and whenever possible,
allo-SCT [IV, B].108Treatment of neutropaenia and thrombocytopaenia. In
lower-risk MDS, neutropaenia and thrombocytopaenia are
less frequent than anaemia, and are rarely isolated or
profound.
Neutrophils are<1500/mm3 in only 7% of lower-risk MDS,
and neutropaenia is rarely associated with life-threatening
infections if no drugs worsening neutropaenia are used. G-
CSF can improve neutropaenia in 60%-75% of these cases and
can be added to anti-infective drugs [III, C], but its prolonged
use has not demonstrated any impact on survival.
Platelets below 50 000/mm3 are seen inw30% of low-risk
MDS. High-dose androgens can improve thrombocytopaenia
in one-third of thrombocytopaenic lower-risk MDS, but
response is generally transient [III, C].111,112 The thrombo-
poietin (TPO) receptor agonist (TPO-RA), romiplostim, at
high doses (500-1000 mg/week) yielded a 55% platelet
response in a phase II trial in patients with lower-risk MDS
and thrombocytopaenia. However, in w15% of patients, a
transient rise in marrow blasts and/or the appearance of
peripheral blasts was seen which was reversible after drug
discontinuation.113 In a randomised phase II study versus
placebo in patients with lower-risk MDS and thrombocyto-
paenia, romiplostim significantly reduced the incidence of
severe bleeding and platelet transfusions.114 While there
was a suspected increase in AML risk upon first analysis, this
was not confirmed by later follow-up.114 Results of a rand-
omised trial in lower-risk MDS patients treated with
eltrombopag, an oral TPO-RA, showed a 47% platelet
response and a reduction in bleeding events with no obvious
safety concerns and no observed rise in marrow blasts.115
TPO-RAs are not approved for MDS in Europe and
currently cannot be recommended outside of clinical trials or
registries at this time. They should also be restricted to pa-
tients without an excess of marrow blasts [II, C].
ATG  cyclosporine (in selected cases, as described
above) and HMAs achieve platelet response in 35%-40% of
cases of lower-risk MDS in addition to erythroid responses
[III, C]99-101 (see Figures 2 and 3).10 https://doi.org/10.1016/j.annonc.2020.11.002Supportive care and chelation therapy in MDS
Supportive care is required in all MDS patients at some
point in the disease and may be the only long-term treat-
ment for unfit patients and those not responding to the
agents described above. In patients requiring repeated RBC
transfusions, administration at a sufficiently high haemo-
globin threshold is recommended (i.e. at least 8 g/dl, and
9 g/dl or even 10g/dl in cases of comorbidities or poor
functional tolerance). A sufficient number of RBC concen-
trates should be transfused each time, over 2 or 3 days if
needed, to increase the haemoglobin level above 10 g/dl
and limit the effects of chronic anaemia, especially on QoL
[IV, A].
Aside from patients receiving myelosuppressive drugs,
prophylactic platelet transfusions are not commonly used.
Prophylactic antibiotics and/or G-CSF are not recommended
in case of neutropaenia, but rapid onset of broad-spectrum
antibiotics is mandatory in case of fever or symptoms of
infection [II, A]. Short-term use of G-CSF during severe in-
fections could be useful in neutropaenic patients.
Psychosocial support and contact with patient support
groups should be offered.
A debate exists about the deleterious effect of iron
overload in MDS patients and the role of iron chelation in
those patients. While heart iron overload is a well-
documented cause of heart failure in children with thal-
assaemia,116,117 its clinical consequences are less certain
in transfused MDS patients, particularly as many have
other causes of cardiac morbidity.118,119 However, car-
diovascular magnetic resonance (CMR) imaging studies
show that heart iron overload [reflected by a decrease in
T2-star (T2*) CMR imaging] is frequent in patients who
have received at least 70-80 RBC concentrates, a frequent
situation in low-risk MDS, and that heart T2* <20 milli-
seconds is associated with decreased left ventricular
ejection fraction and a risk of heart failure.120 Retro-
spective studies suggest that adequate chelation in highly-
transfused patients may improve their survival [IV,
C].98,121 The TELESTO trial prospectively examined iron
chelation in lower-risk MDS, suggesting a significant
improvement in event-free survival in chelated pa-
tients.122 However, this was a composite endpoint,
including survival and cardiac and liver function.
Published recommendations for iron chelation therapy
[I, V]123 generally advocate starting chelation in patients
with a relatively favourable prognosis (i.e. low- or inter-
mediate-1-risk MDS) who have received 20-60 RBC con-
centrates, or if serum ferritin rises above 1000-2500 U/l.
Potential candidates for allo-SCT should, however, be
chelated early. Indeed, although the underlying mecha-
nisms are unclear, it appears that even a relatively moder-
ate iron overload before allo-SCT is associated with
increased transplant-related mortality [III, B].81,82,124 Che-
lation may also be strongly recommended in patients with
lower-risk MDS who are not candidates for allo-SCT but
have signs of major iron overload, including significantly
reduced cardiac T2* by MRI imaging [III, B].Volume xxx - Issue xxx - 2020
P. Fenaux et al. Annals of OncologyIron chelation is made easier by the availability of oral
iron chelators (especially deferasirox) in addition to the
classical parenteral deferoxamine. Deferasirox cannot be
used in patients with renal failure.125 Deferiprone, another
oral iron chelator, is currently not approved for use in MDS
in most countries because it can also cause neutropaenia in
a small number of patients, which is problematic in MDS.126Recommendations Azacitidine is recommended in patients with higher-risk
MDS without major comorbidities not immediately
eligible for allo-SCT [I, A].
 AML-like ChT is recommended for fit patients (generally
<70 years of age) with favourable cytogenetics accord-
ing to IPSS and marrow blasts 10%, preferably as a
bridge to allo-SCT [I, B].
 Allo-SCT should be proposed to all higher-risk MDS pa-
tients <70 years old without major comorbidities and
with a donor [I, A].
 Reducing the marrow blast count before allo-SCT with
AML-like ChT or HMAs is generally considered when
marrow blasts are 10%, especially for non-
myeloablative allo-SCT [III, A].
 ESAs (especially EPO alpha) are recommended for the
first-line treatment of anaemia in lower-risk MDS in pa-
tients without del(5q) [I, A].
 For transfusion-dependent anaemia of lower-risk MDS
with del(5q), LEN is the most effective drug [I, A].
 After ESA failure, ATG ( cyclosporine) has efficacy in
specific younger patient cohorts of lower-risk MDS [II, B].
 After ESA failure in RBC transfusion-dependent MDS-RS,
luspatercept is recommended [I, A].
 Other second-line treatments for anaemia after ESA fail-
ure include LEN  ESA [II, B] and HMAs [II, B], but they
are not approved in Europe for this indication.
 TPO-RAs (romiplostim, eltrombopag) have some efficacy
in cases of severe thrombocytopaenia but they are not
approved in MDS and should only be used in patients
with marrow blasts <5% [II, C].
 In patients with transfusion iron overload, iron chelation
is strongly recommended in candidates for allo-SCT
[III, B].
 In non-transplant candidates with lower-risk MDS, iron
chelation is strongly recommended in patients with ma-
jor iron overload (e.g. significantly reduced cardiac T2*)
[III, B], but its use is more controversial in patients
without major iron overload [I, V].PERSONALISED MEDICINE
Most prognostic factors in MDS have been defined irre-
spective of treatment and it is often unclear if they are
predictive of efficacy of a given treatment.
The IPSS and IPSS-R offer a valuable means of patient
stratification and have therefore served as a basis for
Figures 2 and 3 to summarise treatment recommendations.
For example, anaemia of lower-risk MDS often responds toVolume xxx - Issue xxx - 2020ESAs, except in case of del(5q) where LEN is very effective.
On the other hand, in higher-risk patients, while azacitidine
has been shown to improve survival, there are currently
limited alternative options (except allo-SCT for a minority of
patients).
Consideration of the patient’s age, PS, comorbidities,
frailty and desire (after adequate information has been
provided by the medical team) is also crucial before making
any treatment decision.
FOLLOW-UP
Except for specific treatments, follow-up of MDS is largely
based on regular blood counts to detect worsening cyto-
paenias [anaemia or severe thrombocytopaenia requiring
transfusions, or severe neutropaenia mandating preventive
measures against infection (e.g. during invasive proced-
ures)] and rapid onset of broad-spectrum antibiotics in case
of symptoms of infection.
Bone marrow examination, with or without karyotype, is
generally triggered by worsening of cytopaenias or the
appearance of circulating blasts rather than being system-
atically carried out at regular intervals.
METHODOLOGY
These Clinical Practice Guidelines were developed in accor-
dance with the ESMO standard operating procedures for
Clinical Practice Guidelines development (http://www.
esmo.org/Guidelines/ESMO-Guidelines-Methodology). The
relevant literature has been selected by the expert authors.
Levels of evidence and grades of recommendation have been
applied using the system shown in supplementary Table S1,
available at https://doi.org/10.1016/j.annonc.2020.11.002.127
Statements without grading were considered justified stan-
dard clinical practice by the authors.
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